Madrigal pharmaceuticals reports inducement grants under nasdaq listing rule 5635(c)(4)

Conshohocken, pa., sept. 14, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that it made an inducement grant to bill sibold on september 11, 2023 in connection with his appointment as madrigal's new president and chief executive officer. the award was granted outside of the company's amended 2015 stock plan under the terms of the company's 2023 inducement plan (which was approved and adopted by the board of directors on september 8, 2023) and was approved by the company's compensation committee in accordance with nasdaq listing rule 5635(c)(4).
MDGL Ratings Summary
MDGL Quant Ranking